Production (Stage)
NurExone Biologic Inc.
NRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.80M | -5.04M | -4.23M | -4.14M | -3.86M |
| Total Depreciation and Amortization | 113.00K | 85.00K | 49.00K | 49.00K | 42.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.28M | 993.00K | 860.00K | 655.00K | 711.00K |
| Change in Net Operating Assets | -5.00K | -923.00K | -461.00K | -320.00K | -480.00K |
| Cash from Operations | -4.41M | -4.89M | -3.79M | -3.76M | -3.58M |
| Capital Expenditure | -440.00K | -649.00K | -670.00K | -368.00K | -309.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.00K | -9.00K | 13.00K | 13.00K | 23.00K |
| Cash from Investing | -449.00K | -658.00K | -657.00K | -355.00K | -286.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.00K | -30.00K | -31.00K | -34.00K | -28.00K |
| Issuance of Common Stock | 3.27M | 6.76M | 5.63M | 5.49M | 5.47M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -850.00K | -850.00K | 196.00K | 131.00K | 95.00K |
| Cash from Financing | 2.39M | 5.88M | 5.79M | 5.58M | 5.54M |
| Foreign Exchange rate Adjustments | -199.00K | -173.00K | 32.00K | 34.00K | -2.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.67M | 159.00K | 1.38M | 1.51M | 1.67M |